| Literature DB >> 24931218 |
Peng Jiang1, Martine Jandrot-Perrus2.
Abstract
The recent introduction of highly effective antiplatelet drugs has contributed to the significant improvement in the treatment of acute coronary syndromes. However, limitations remain. Recurrence of ischaemic vascular events results in poor prognosis. Drugs of high antithrombotic efficacy are associated with an increased risk of bleeding, which is important in patients at risk of stroke. An attractive target for the development of new antithrombotics is platelet glycoprotein VI (GPVI) because its blockade seems to combine ideally efficiency and safety. In this review, we summarise current knowledge on the physiological role of GPVI in haemostasis and thrombosis. We also discuss evidence regarding the effectiveness and safety of strategies to inhibit GPVI.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24931218 DOI： 10.1016/j.drudis.2014.06.005
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851